<article>
    <h2>Sitting for a long time shrinks your brain even if you exercise</h2>
    <div>
 <div>
  <h3>Summary</h3>
  <p>
   The article is a research report that investigates the association between leukocyte telomere length (LTL) and Alzheimer's disease (AD) biomarkers, as well as cognitive performance. Telomeres are protective caps on the ends of chromosomes that shorten with age and cellular stress. Shorter LTL has been associated with various age-related diseases. The study explores whether LTL is related to AD-related pathology and cognitive decline in a group of older adults.
  </p>
  <p>
   The researchers analyzed data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. They measured LTL from blood samples and examined its relationship with AD biomarkers obtained from cerebrospinal fluid (CSF) and amyloid PET scans. The AD biomarkers included measures of amyloid plaques (Aβ), tau tangles (tau and p-tau), and neurodegeneration (measured by the level of total tau). Cognitive performance was assessed using various neuropsychological tests that measure memory, executive function, and overall cognition.
  </p>
  <p>
   The study found that shorter LTL was associated with several AD-related abnormalities. Specifically, shorter LTL was correlated with higher levels of tau and p-tau in the CSF, indicating increased tau pathology. However, the study did not find a strong association between LTL and amyloid plaque burden as measured by CSF Aβ or amyloid PET imaging. They also observed a modest association between shorter LTL and poorer cognitive performance, particularly in tests of memory and executive function.
  </p>
  <p>
   The researchers also investigated whether LTL was associated with the rate of cognitive decline over time. They found that individuals with shorter LTL at baseline experienced a faster rate of cognitive decline compared to those with longer LTL. This suggests that LTL may be a marker of resilience or vulnerability to AD-related cognitive decline.
  </p>
  <p>
   Overall, the findings suggest that shorter LTL is associated with increased tau pathology, poorer cognitive performance, and a faster rate of cognitive decline in older adults. The study highlights the potential role of telomere shortening in the pathogenesis of AD and suggests that LTL may be a useful biomarker for identifying individuals at risk for AD-related cognitive decline.
  </p>
  <h3>Key Points</h3>
  <ul>
   <li>Shorter leukocyte telomere length (LTL) is associated with Alzheimer's disease (AD)-related pathology and cognitive decline.</li>
   <li>Shorter LTL is correlated with higher levels of tau and p-tau in cerebrospinal fluid (CSF), indicating increased tau pathology.</li>
   <li>The study did not find a strong association between LTL and amyloid plaque burden.</li>
   <li>Shorter LTL is associated with poorer cognitive performance, particularly in tests of memory and executive function.</li>
   <li>Individuals with shorter LTL at baseline experienced a faster rate of cognitive decline over time.</li>
   <li>LTL may be a marker of vulnerability to AD-related cognitive decline.</li>
  </ul>
 </div>
 </div>
</article>
